Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | BMC Cancer

Fig. 2

From: Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma

Fig. 2

Combinatory effects produced by ZOL and Ad-delE1B55. a Cells were treated with different concentrations of ZOL and doses of Ad-delE1B55 as indicated for 5 days. As for combination of ZOL and Ad-delE1B55, cells were treated with different concentrations of ZOL and Ad-delE1B at a fixed dose (MSTO-211H and NCI-H28: 1.5 × 103 vp/cell, NCI-H226: 5 × 103 vp/cell). The cell viabilities were measured with the WST assay. Averages and SE bars are shown (n = 3). CI values based on the cell viabilities were determined by different Fa points with the CalcuSyn software. We repeated this assay for 3 times and show representative data. b Proliferation of cells treated with ZOL and/or either Ad-delE1B55 or Ad-LacZ as a control. Cells were treated with ZOL (MSTO-211H: 10 μM, NCI-H226: 60 μM, NCI-H28: 100 μM) and/or Ad-delE1B55 or Ad-LacZ (MSTO-211H: 4.5 × 103 vp/cell, NCI-H226: 2 × 103 vp/cell, NCI-H28: 3 × 103 vp/cell). Live cell numbers were determined with the dye exclusion test. Averages and SEs are shown. We repeated this assay for 3 times in total and show representative data. *p < 0.05, compared the ZOL plus Ad-delE1B55-treated group with Ad-LacZ-, ZOL-, Ad-delE1B55-, ZOL plus Ad-LacZ-treated cells groups

Back to article page